Novel Molecular Biologic Formats Require Tailored CMC Solutions

Source: Lonza

New molecular formats and other recombinant proteins present facility- and product-specific development requirements that often render platform approaches inappropriate. Accordingly, addressing the most pressing challenges in process and analytical development associated with novel molecular biologic formats requires a keen understanding of the applicable tools and strategies.

Recently, Andrew Brown, a Support Manager for Global Process Development at Lonza Biologics, presented a webinar sharing Lonza’s integrated drug substance and drug product CMC strategy. He also explored technical case studies from process and analytical development that provide insight into how we have delivered tailored, product-specific solutions and enabled the acceleration of novel molecular formats into the clinic.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online